Hepatitis B and Liver Cancer (Hepatocellular Carcinoma)

From a western clinical perspective, chronic hepatitis B is a preventable infection and a well‑established carcinogen for hepatocytes. After acute exposure, immune‑tolerant or immune‑active phases can lead to persistent viremia. HBV’s covalently closed circular DNA stabilizes persistence, and fragments of viral DNA integrate into host chromosomes. Viral proteins—especially HBx—modulate transcription and signaling pathways (e.g., p53, Wnt/β‑catenin), creating selective pressures that favor malignant clones. In parallel, chronic necroinflammatory injury stimulates fibrogenesis; cirrhosis, a preneoplastic state, markedly increases HCC risk. Unlike many liver diseases, HBV can produce HCC without cirrhosis because of these direct oncogenic mechanisms. Epidemiologically, HBV explains about half of global HCC, with the largest impact in regions with early‑life transmission. The REVEAL‑HBV study established a robust, graded relationship between serum HBV DNA and HCC risk, informing modern risk scores. Cofactors such as aflatoxin exposure, heavy alcohol use, metabolic syndrome/NAFLD, and co‑infection with HDV or HCV further elevate risk. Prevention operates on several levels: universal vaccination with a timely birth dose and perinatal prophylaxis have reduced childhood HCC dramatically in Taiwan and other settings. For people with chronic infection, long‑term suppression with high‑barrier nucleos(t)ide analogs reduces necroinflammation, fibrosis progression, and HCC incidence, but residual risk persists, necessitating surveillance. Guidelines recommend semiannual ultrasound, with or without AFP, for all patients with HBV cirrhosis and for high‑risk non‑cirrhotic groups (e.g., Asian men over 40, Asian women over 50, individuals from Africa over 20, and those with a family history of HCC). When small tumors are found early, curative therapies—resection, ablation, or transplantation—offer the best outcomes. More advanced disease may be managed with locoregional approaches (e.g., TACE) and systemic therapies, including immune‑checkpoint inhibitors and anti‑angiogenic agents. Throughout, management of modifiable risks—alcohol abstinence, metabolic control, and food safety to limit aflatoxin—complements antiviral therapy to lower cancer risk.

Traditional East Asian medicine interprets chronic hepatitis and liver tumors through functional patterns rather than viral etiology. Long‑standing liver heat and dampness are thought to congeal into phlegm and blood stasis, while dietary excess and toxins burden the spleen‑stomach and the liver. Over time, this terrain fosters “abdominal masses.” Treatment aims to clear heat and dampness, move qi and blood, resolve toxin and phlegm, and support essence and spleen function. In practice, formulas such as Xiao Chai Hu Tang (Sho‑saiko‑to) have been used to harmonize the lesser yang, support digestion, and address chronic hepatitis symptoms. Some observational research has explored its potential to reduce progression, though later reports raised safety concerns (e.g., interstitial pneumonia), underscoring the need for careful, supervised use. In Ayurveda, Phyllanthus amarus (Bhumyamalaki) and turmeric (Curcuma longa) are traditional hepatics; preclinical studies suggest antiviral or anti‑inflammatory effects, but high‑quality clinical evidence for HCC prevention remains limited. Integrative care aligns with several biomedical risk‑reduction pillars: abstaining from alcohol, avoiding spoiled or mold‑contaminated foods, maintaining a balanced diet and healthy weight, and supporting stress resilience. Acupuncture and mind‑body practices may help with fatigue, sleep disturbance, pain, and procedural anxiety during antiviral or oncologic treatments, although they do not treat HBV or HCC directly. Contemporary integrative clinicians often emphasize partnership: using guideline‑directed antiviral therapy and cancer surveillance while personalizing diet, movement, and supportive therapies to improve quality of life and adherence. In this view, traditional frameworks offer a language for terrain‑focused care that sits alongside virologic suppression and evidence‑based surveillance to reduce overall risk and support patients across the disease spectrum.